Oxford BioMedica wins second $100 mln gene therapy contract – Nasdaq
Nasdaq |
Oxford BioMedica wins second $100 mln gene therapy contract
Nasdaq LONDON, Feb 15 (Reuters) – Britain’sOxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it … Oxford BioMedica share price rises on $100m gene therapy deal with BioverativCity A.M. Oxford BioMedica signs agreement with BioverativStock Market Wire |
City A.M. |
Oxford BioMedica wins second $100 million gene therapy contract
Reuters The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis’s pioneering leukemia treatment Kymriah. Oxford Bio, which listed in London in 1996 after being spun out of … Oxford BioMedica share price rises on $100m gene therapy deal with BioverativCity A.M. Oxford BioMedica signs agreement with BioverativStock Market Wire Oxford BioMedica Inks Potential USD100 Million Deal With BioverativLondon South East (blog) Proactive Investors UK all 9 news articles » |
Germiston City News |
Stem cell therapy and storage a new healthcare revolution
Germiston City News The GCN spoke to Erna West, the general manager and a product specialist for CryoSave, South Africa’s leading stem cell storage company about the options available to parents regarding storing their baby’s umbilical cord stem cells at birth to help … |